Aurinia Pharmaceuticals Inc. (AUPH) Lifts 2026 Revenue Outlook

What happened

Aurinia raised its 2026 total revenue guidance to $325M–$330M from $315M–$325M and narrowed net product sales guidance to $310M–$315M. It reported $486.9M in cash, cash equivalents, restricted cash and investments as of September 30, 2026.

Confirmed

Global impact / market context

A higher revenue range means management expects more sales from its lupus treatment, which can support profit expectations. The narrowed product sales range suggests better visibility on core demand, while $486.9M in cash and investments reduces the need to raise borrowed money or sell new shares.

Analyst inference

The guidance raise and share buybacks point to a company funding growth from its own cash rather than new financing. The initiated Phase 4 combination study adds clinical risk, but a positive result could widen use of its existing treatment and support future revenue.

Analyst inference

What to watch

1. Whether 2026 total revenue lands within the raised $325M–$330M range, and whether net product sales reach $310M–$315M, will show if the improved outlook holds. Confirmed
2. Further share repurchases could reduce the share count and lift earnings per share, which means profit divided by shares outstanding; watch whether buybacks continue at similar pace. Analyst inference
3. Results from the initiated PRESERVE Phase 4 combination study could expand use of LUPKYNIS if outcomes improve, so trial progress and any readouts are key clinical milestones to track. Proposed

Evidence

• Original source link unavailable